Science Friday

How A Fringe Idea Led To Lifesaving Cancer Treatments

December 10, 2025

Key Takeaways Copied to clipboard!

  • Dr. Rakesh K. Jain's research, which focuses on the tumor microenvironment (the "soil") rather than just the cancer cells (the "seed"), has led to seven FDA-approved cancer treatments by normalizing tumor vasculature. 
  • Tumors are complex organs with abnormal blood vessels that impede drug delivery and effectiveness, a problem that Jain initially approached using chemical engineering principles like mass transfer. 
  • The pressure inside tumors, often caused by the extracellular matrix, collapses blood vessels, but this can be normalized using existing, inexpensive drugs like the blood pressure medication Losartan, which also shows promise in reducing edema in brain tumors like glioblastoma. 

Segments

Jain’s Outsider Perspective
Copied to clipboard!
(00:02:20)
  • Key Takeaway: Dr. Jain acknowledges his research ideas have historically been counterintuitive and against the grain, leading to an uphill battle.
  • Summary: Dr. Rakesh K. Jain views his research ideas as counterintuitive, which historically created an uphill battle in the scientific community. Despite this resistance, achieving positive results proved very gratifying. He confirms that his focus on the ‘soil’ rather than the ‘seed’ (tumor cells) was considered radical.
Defining Tumor Soil Complexity
Copied to clipboard!
(00:03:00)
  • Key Takeaway: A tumor is an organ with its own rules, and the ‘soil’ environment confers resistance to all forms of therapy.
  • Summary: A tumor is more complex than just a bag of cancer cells; it functions like an organ with internal rules. The surrounding soil environment dictates tumor growth and confers resistance to radiation, chemotherapy, and immunotherapy. This soil includes abnormal blood vessels, matrix components like collagen, immune cells, neuronal cells, and even the tumor microbiome.
Engineering Approach to Drug Delivery
Copied to clipboard!
(00:05:45)
  • Key Takeaway: Jain applied chemical engineering principles of mass transfer to discover that drugs largely bypass tumors or enter heterogeneously due to poor blood flow.
  • Summary: Trained as a chemical engineer, Jain modeled drug delivery as a mass transfer problem, investigating how substances move into tumors. Using surgically implanted glass windows in animal models, he visualized that most injected drugs bypass the tumor via a ‘beltway’ around it. Furthermore, the drug delivery that does occur is highly heterogeneous, leaving some cells untreated.
Blood Flow Visualization Discoveries
Copied to clipboard!
(00:09:50)
  • Key Takeaway: Visualizing tumor vasculature revealed that blood flow is brisk in some areas but completely absent in others, despite the presence of visible vessels.
  • Summary: By visualizing blood flow in tumors over time using specialized microscopes, Jain observed that flow is not uniform; some regions have brisk flow while others have none. This phenomenon, where traffic stops in a tube, was identified as a key problem in drug delivery. This visualization technique was developed using surgically implanted windows in animal models.
Initial Rejection of Soil Hypothesis
Copied to clipboard!
(00:12:10)
  • Key Takeaway: Jain’s initial grant proposals focusing on drug delivery and tumor vasculature were rejected for five years because the field insisted on focusing solely on cancer cell genetics.
  • Summary: The field initially dismissed Jain’s work on drug delivery as unimportant, urging him to focus on cancer cell genetics instead. He faced six grant rejections before receiving his first NIH grant in 1980, five years after finishing his PhD. He persisted because he believed improving blood flow was essential to effective cancer treatment.
Anti-Angiogenic Drugs Paradox
Copied to clipboard!
(00:15:45)
  • Key Takeaway: Anti-angiogenic drugs, intended to starve tumors by cutting off blood supply, paradoxically improve drug delivery and enhance immunotherapy when combined with chemotherapy.
  • Summary: The prevailing dogma was to starve tumors, leading to the development of anti-angiogenic drugs like Bevasuzmab (Avastin) intended to inhibit growth factors (VEGF). While these drugs failed when used alone, they succeeded when combined with chemotherapy, suggesting they were improving drug delivery. Jain’s research showed these drugs temporarily normalize vessels, which in turn improves immunotherapy effectiveness, leading to seven FDA approvals.
Tumor Pressure and Matrix Normalization
Copied to clipboard!
(00:21:26)
  • Key Takeaway: Tumors exert pressures higher than arterial blood pressure, collapsing vessels, a process driven by the matrix, which can be normalized using the cheap drug Losartan.
  • Summary: Human tumors can generate pressures exceeding 120 mmHg, which compresses and collapses blood vessels, especially in dense tumors like pancreatic cancer (which is 95% soil). This compression is largely caused by the extracellular matrix. The blood pressure drug Losartan, costing less than a dollar a day, was discovered to reduce this matrix, thereby normalizing vessel structure.
Losartan’s Effect on Brain Tumors
Copied to clipboard!
(00:24:56)
  • Key Takeaway: Losartan not only normalizes tumor vasculature but also decreases edema (swelling) in glioblastoma, potentially overcoming the immunosuppressive effects of steroids used to treat that swelling.
  • Summary: In glioblastoma, a deadly brain tumor, immune checkpoint blockers often increase edema, requiring patients to take immunosuppressive steroids, which counteracts the therapy. Jain’s recent findings show that Losartan decreases this edema, allowing immune therapy to work without the need for steroids. Securing funding for a clinical trial for this generic drug is currently difficult due to lack of pharmaceutical incentive.
Threats to Scientific Funding
Copied to clipboard!
(00:27:14)
  • Key Takeaway: The biggest threat to cancer research is the drastic reduction in NIH funding success rates, which is now as low as 4%, jeopardizing the work of young scientists.
  • Summary: The success rate for NIH grant funding has plummeted from about 25% early in Jain’s career to as low as 4% currently, which is hurting patients by preventing promising ideas from being tested. This lack of funding, coupled with restrictive immigration policies affecting international talent, risks the U.S. losing its leadership in scientific innovation. Foundations are urged to step in to support young scientists who are being ‘killed’ by the funding drought.
Advice for Out-of-Box Thinkers
Copied to clipboard!
(00:31:35)
  • Key Takeaway: Scientists pursuing unconventional ideas must hang in there, recognizing the fine line between determined persistence and foolish stubbornness, and embrace being wrong.
  • Summary: The primary advice for those pursuing outside-the-box ideas is to not give up, while carefully navigating the fine line between stubbornness and stupidity. Being wrong is an expected part of science; if everything goes right all the time, there is likely an unrecognized problem. The dual purpose of science is personal joy and understanding nature, coupled with serving humanity by improving human well-being.